Published in Exp Cell Res on February 15, 2004
The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin Exp Rheumatol (2008) 1.16
High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesis. Bone (2008) 1.14
Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling. Arthritis Res Ther (2008) 0.90
A dominant function of p38 mitogen-activated protein kinase signaling in receptor activator of nuclear factor-kappaB ligand expression and osteoclastogenesis induction by Aggregatibacter actinomycetemcomitans and Escherichia coli lipopolysaccharide. J Periodontal Res (2008) 0.88
Inhibition of osteoclast formation and function by bicarbonate: role of soluble adenylyl cyclase. J Cell Physiol (2009) 0.88
Gallium modulates osteoclastic bone resorption in vitro without affecting osteoblasts. Br J Pharmacol (2010) 0.87
Proteoglycans and osteolysis. Methods Mol Biol (2012) 0.77
Tyrosine kinase inhibitor tyrphostin AG490 retards chronic joint inflammation in mice. Inflammation (2014) 0.77
Inositol hexakisphosphate inhibits osteoclastogenesis on RAW 264.7 cells and human primary osteoclasts. PLoS One (2012) 0.76
Protective effects of fermented rice vinegar sediment (Kurozu moromimatsu) in a diethylnitrosamine-induced hepatocellular carcinoma animal model. J Clin Biochem Nutr (2011) 0.75
WSS25, a sulfated polysaccharide, inhibits RANKL-induced mouse osteoclast formation by blocking SMAD/ID1 signaling. Acta Pharmacol Sin (2015) 0.75
Increased bone formation in osteocalcin-deficient mice. Nature (1996) 4.91
Long-lasting treated mosquito nets: a breakthrough in malaria prevention. Bull World Health Organ (2001) 2.99
Reducing the cost of HIV antibody testing. Lancet (1993) 2.18
Immunogenicity and safety of measles vaccine in ill African children. Int J Epidemiol (1988) 1.67
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta (2004) 1.57
Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest (1997) 1.49
Plasmodium falciparum associated placental pathology: a light and electron microscopic and immunohistologic study. Am J Trop Med Hyg (1989) 1.44
Osteoclastic resorption of calcium phosphate ceramics with different hydroxyapatite/beta-tricalcium phosphate ratios. Biomaterials (1997) 1.43
Identifying the reasons for low immunization coverage. A case study of Yaounde (United Republic of Cameroon). Rev Epidemiol Sante Publique (1982) 1.36
Public health implications of emerging zoonoses. Rev Sci Tech (2000) 1.36
Correlates of osteoprotegerin levels in women and men. Osteoporos Int (2002) 1.31
The effects of cytokines and growth factors on osteoblastic cells. Bone (1995) 1.28
Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity (2003) 1.24
Osteoclastic acidification pathways during bone resorption. Bone (2002) 1.18
Characterization of osteoclast precursors in human blood. Br J Haematol (2000) 1.14
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci (2007) 1.14
Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol (2006) 1.14
Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. Ann Rheum Dis (2011) 1.12
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone (2005) 1.11
Osteogenic potential in vitro of human bone marrow cells cultured on macroporous biphasic calcium phosphate ceramic. J Biomed Mater Res (1999) 1.10
DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Bone (2006) 1.05
Tumor necrosis factor inhibits collagen and fibronectin synthesis in human dermal fibroblasts. FEBS Lett (1988) 1.04
Influence of biphasic calcium phosphate granulometry on bone ingrowth, ceramic resorption, and inflammatory reactions: preliminary in vitro and in vivo study. J Biomed Mater Res (1999) 1.03
Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochem Biophys Res Commun (2006) 1.01
Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol (2007) 0.98
Bone remodelling and tumour grade modifications induced by interactions between bone and swarm rat chondrosarcoma. Histol Histopathol (2002) 0.97
Reducing the cost of HIV antibody testing. Lancet (1993) 0.97
Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer (2005) 0.96
Effect of transforming growth factor-beta 1 (TGF-beta 1) on matrix synthesis by monolayer cultures of rabbit articular chondrocytes during the dedifferentiation process. Exp Cell Res (1992) 0.95
Therapeutic approach of primary bone tumours by bisphosphonates. Curr Pharm Des (2010) 0.95
Fullerenes in the cretaceous-tertiary boundary layer. Science (1994) 0.94
Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochem Biophys Res Commun (2002) 0.93
IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. Cytokine (2010) 0.93
Proteases and bone remodelling. Cytokine Growth Factor Rev (2008) 0.93
Metatarsal giant cell tumors and giant cell reparative granuloma are similar entities. Clin Orthop Relat Res (2003) 0.92
Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models. Cancer Gene Ther (2010) 0.92
Lymphatic filariasis: setting the scene for elimination. Trans R Soc Trop Med Hyg (2001) 0.91
Elements 112 to 119: were they present in meteorites? Science (1969) 0.90
The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. Calcif Tissue Int (2005) 0.90
Transforming growth factor-beta 1 (TGF-beta 1) up-regulation of collagen type II in primary cultures of rabbit articular chondrocytes (RAC) involves increased mRNA levels without affecting mRNA stability and procollagen processing. J Cell Physiol (1992) 0.90
STD vaccines--an overview. Genitourin Med (1997) 0.90
Key roles of the OPG-RANK-RANKL system in bone oncology. Expert Rev Anticancer Ther (2007) 0.89
Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment. Biochim Biophys Acta (2009) 0.88
Food-borne outbreak of Giardia lamblia. Am J Public Health (1990) 0.88
Biodegradation of synthetic biphasic calcium phosphate by human monocytes in vitro: a morphological study. Biomaterials (1996) 0.87
Leukaemia inhibitory factor (lif) is expressed in hypertrophic chondrocytes and vascular sprouts during osteogenesis. Cytokine (2002) 0.86
High and low affinity receptors for human interleukin for DA cells/leukemia inhibitory factor on human cells. Molecular characterization and cellular distribution. J Biol Chem (1992) 0.86
Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med (2008) 0.86
LPS increases biomaterial degradation by human monocytes in vitro. J Biomed Mater Res (1997) 0.86
The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets. Sarcoma (2011) 0.85
Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. J Thromb Haemost (2011) 0.85
Regulation of osteoclast protease expression by RANKL. Biochem Biophys Res Commun (2003) 0.85
Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53. Oncogene (2007) 0.85
Influence of bone environment on ceramic osteointegration in spinal fusion: comparison of bone-poor and bone-rich sites. Eur Spine J (2001) 0.84
Transmission FT-IR microspectroscopy of mineral phases in calcified tissues. C R Acad Sci III (1998) 0.83
A composite element binding the vitamin D receptor and the retinoic X receptor alpha mediates the transforming growth factor-beta inhibition of decorin gene expression in articular chondrocytes. J Biol Chem (2001) 0.83
Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer. Cancer Res (1995) 0.82
Influence of metal ion solutions on rabbit osteoclast activities in vitro. Histol Histopathol (2002) 0.82
Dlx homeobox gene family expression in osteoclasts. J Cell Physiol (2010) 0.81
Neointimal hyperplasia after stenting in a human mammary artery organ culture. J Vasc Res (2004) 0.81
Presence of leukaemia inhibitory factor (LIF) and LIF-receptor chain (gp190) in osteoclast-like cells cultured from human giant cell tumour of bone. Ultrastructural distribution. Cytokine (1999) 0.81
Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells? Histol Histopathol (2009) 0.81
Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK. Biochim Biophys Acta (2004) 0.81
Human amniotic tumor that induces new bone formation in vivo produces growth-regulatory activity in vitro for osteoblasts identified as an extended form of basic fibroblast growth factor. Cancer Res (1996) 0.81
Growth hormone stimulatory effects on osteoclastic resorption are partly mediated by insulin-like growth factor I: an in vitro study. Bone (1998) 0.80
Modulation of human dermal fibroblast extracellular matrix metabolism by the lymphokine leukoregulin. J Cell Biol (1991) 0.80
A new experimental rat model of osteosarcoma established by intrafemoral tumor cell inoculation, useful for biology and therapy investigations. Tumour Biol (2005) 0.79
Microwave balloon angioplasty effectively seals arterial dissections in an atherosclerotic rabbit model. J Am Coll Cardiol (1994) 0.79
Pharmacological blocking of the osteoclastic biocorrosion of surgical stainless steel in vitro. J Biomed Mater Res A (2012) 0.78
Osteoclastic resorption of biphasic calcium phosphate ceramic in vitro. J Biomed Mater Res (1997) 0.78
Growth hormone-loaded macroporous calcium phosphate ceramic: in vitro biopharmaceutical characterization and preliminary in vivo study. J Biomed Mater Res (1998) 0.78
Cysteine protease production by human osteosarcoma cells (MG63, SAOS2) and its modulation by soluble factors. Cytokine (2000) 0.78
Increased levels of leukaemia inhibitory factor (LIF) in urine and tissue culture supernatant from human primary bone tumours. Cytokine (1998) 0.78